Keyword Analysis & Research: favipiravir
Keyword Research: People who searched favipiravir also searched
Search Results related to favipiravir on Search Engine
-
Favipiravir - Wikipedia
https://en.wikipedia.org:443/wiki/Favipiravir
WEBFavipiravir, sold under the brand name Avigan among others, [3] is an antiviral medication used to treat influenza in Japan. [4] . It is also being studied to treat a number of other viral infections, including SARS-CoV-2. [4] . Like the experimental antiviral drugs T-1105 and T-1106, it is a pyrazinecarboxamide derivative. [5]
DA: 54 PA: 97 MOZ Rank: 76
-
Favipiravir: Uses, Interactions, Mechanism of Action | DrugBank …
https://go.drugbank.com:443/drugs/DB12466
WEBOct 20, 2016 · Summary. Favipiravir is an antiviral used to manage influenza, and that has the potential to target other viral infections. Generic Name. Favipiravir. DrugBank Accession Number. DB12466. Background.
DA: 43 PA: 94 MOZ Rank: 86
-
Safety and efficacy of favipiravir in COVID-19 patients with …
https://pneumonia.biomedcentral.com:443/articles/10.1186/s41479-023-00124-6
WEBFeb 25, 2024 · Favipiravir administered for ten days to patients with COVID-19 and pneumonia did not improve outcomes compared with placebo. Although this is an underpowered negative study, efficacy results align with other randomized trials. However, in the present study, the non-serious adverse events were more frequent in the …
DA: 5 PA: 44 MOZ Rank: 44
-
Favipiravir for the treatment of patients with COVID-19: a …
https://bmcinfectdis.biomedcentral.com:443/articles/10.1186/s12879-021-06164-x
WEBMay 27, 2021 · Favipiravir induces viral clearance by 7 days and contributes to clinical improvement within 14 days. The results indicated that favipiravir has strong possibility for treating COVID-19, especially in patients with mild-to-moderate illness.
DA: 52 PA: 91 MOZ Rank: 50
-
Clinical antiviral efficacy of favipiravir in early COVID-19 …
https://bmcinfectdis.biomedcentral.com:443/articles/10.1186/s12879-023-08835-3
WEBJan 15, 2024 · Favipiravir, an anti-influenza drug, has in vitro antiviral activity against SARS-CoV-2. Clinical trial evidence to date is inconclusive. Favipiravir has been recommended for the treatment of COVID-19 in some countries.
DA: 12 PA: 7 MOZ Rank: 17
-
Is favipiravir useful in treating people with COVID‐19?
https://www.cochrane.org:443/CD015219/INFECTN_favipiravir-useful-treating-people-covid-19
WEBWhat is favipiravir? Favipiravir is a medicine that can fight viruses. It is usually taken by mouth. Originally used for treating other viral infections, favipiravir has been suggested as a potential treatment for COVID-19 as it prevents the reproduction of the virus.
DA: 26 PA: 43 MOZ Rank: 98
-
Benefits of treatment with favipiravir in hospitalized patients for
https://virologyj.biomedcentral.com:443/articles/10.1186/s12985-021-01577-1
WEBPublished: 25 May 2021. Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case–control study. Anıl Ucan, Pamir Cerci, Serdar Efe, Hakan Akgun, Ahmet Ozmen, Aysel Yagmuroglu, Muzaffer Bilgin & Deniz Avci. Virology Journal 18, Article number: 102 ( 2021 ) Cite this article. 11k Accesses.
DA: 1 PA: 91 MOZ Rank: 32
-
Monographs on Favipiravir and on Favipiravir tablets …
https://cdn.who.int:443/media/docs/default-source/medicines/imwp-favipiravir-monographs.pdf?sfvrsn=212299e1_13&download=true
WEB3 IMWP MONOGRAPH ON FAVIPIRAVIR AND FAVIPIRAVIR TABLETS (Rev1 - 06 August 2021) 41 Reference Spectrum 42 43 Water: Not more than 0.6% (0.1g, coulometric titration3). 44 Assay: Weigh accurately about 20 mg each of Favipiravir and IMWP RS on Favipiravir 45 (separately determine the water in the Karl-Fisher coulometric titration …
DA: 49 PA: 93 MOZ Rank: 59
-
Favipiravir In Adults with Moderate to Severe COVID-19: A Phase …
https://www.medrxiv.org:443/content/10.1101/2021.11.08.21265884v1
WEBNov 9, 2021 · Favipiravir In Adults with Moderate to Severe COVID-19: A Phase 3 Multicentre, Randomized, Double-Blinded, Placebo-Controlled Trial | medRxiv. Follow this preprint.
DA: 68 PA: 57 MOZ Rank: 99
-
Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir
https://wwwnc.cdc.gov:443/eid/article/25/10/19-0607_article
WEBFavipiravir is a broad-spectrum antiviral drug that inhibits viral RNA polymerase, an enzyme recognized as an attractive target because of its critical role in virus replication and high degree of conservation ( 8 ).
DA: 73 PA: 70 MOZ Rank: 6
